uniQure (NASDAQ:QURE) Given Consensus Recommendation of “Buy” by Brokerages

Shares of uniQure (NASDAQ:QURE) have received a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $40.00.

A number of research analysts recently commented on QURE shares. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Wednesday. Finally, Leerink Partners raised their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.74% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP bought a new stake in shares of uniQure during the third quarter worth $49,000. China Universal Asset Management Co. Ltd. increased its position in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc bought a new stake in uniQure during the 3rd quarter worth about $53,000. Quarry LP acquired a new position in uniQure during the 3rd quarter valued at about $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of uniQure in the 3rd quarter valued at about $69,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Performance

NASDAQ:QURE opened at $14.63 on Monday. The firm’s 50-day moving average is $14.70 and its 200-day moving average is $9.19. The company has a market cap of $713.07 million, a price-to-earnings ratio of -2.95 and a beta of 0.39. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. Equities research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.